Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Ginkgo Bioworks Holdings, Inc. (DNA) vs Silence Therapeutics PLC Sponsored ADR (SLN)

Ginkgo Bioworks Holdings, Inc. and Silence Therapeutics PLC Sponsored ADR are both Biotechnology companies. Ginkgo Bioworks Holdings, Inc. and Silence Therapeutics PLC Sponsored ADR are of similar size ($697.3M and $683.6M). Ginkgo Bioworks Holdings, Inc. grew revenue faster over the last twelve months: −37.0% against −97.0%. Silence Therapeutics PLC Sponsored ADR has the higher net margin (0.00% vs −219.6%) and the higher return on invested capital (0.00% vs −161.9%). Across the 17 metrics below, Silence Therapeutics PLC Sponsored ADR leads on 9 and Ginkgo Bioworks Holdings, Inc. on 8.

Valuation

Metric DNA SLN Biotechnology median
P/E n/m n/m 7.88
P/S 5.00 629.45 11.47
P/B 1.57 13.73 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 5.77 543.65 10.73
Earnings yield (47.00%) (11.45%) (28.84%)
Free cash flow yield (26.32%) (8.01%) (23.03%)

Profitability

Metric DNA SLN Biotechnology median
Gross margin 68.04% 79.50% 65.16%
Operating margin (231.13%) 0.00% 0.00%
Net margin (219.60%) 0.00% 0.00%
Free cash flow margin (131.57%) 0.00% 0.00%
Return on equity (56.29%) (90.41%) (57.72%)
Return on assets (26.19%) (44.14%) (49.22%)
Return on invested capital (161.94%) 0.00% 0.00%

Growth

Metric DNA SLN Biotechnology median
Revenue growth (TTM) (37.02%) (96.97%) 5.64%
EPS growth (last fiscal year) 46.49% (90.91%) —
Revenue growth, 5-year CAGR 17.29% (39.74%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNA SLN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.57 7.42 4.73
Net debt to EBITDA 1.63 0.94 0.96

Dividend

Metric DNA SLN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DNA SLN Biotechnology median
Market cap 683.64m 697.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack